Positive One-Year Data from Phase 2 Study of Pegcetacoplan i

Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Switzerland , Stockholm , Sweden , Australia , America , Lissa Pavluk , Meredith Kaya , Fadi Fakhouri , Lydia Abad Franch , Caroline Baumal , Exchange Commission , Apellis Pharmaceuticals Inc , Sobi Investor Relations Team , European Renal Association , Nasdaq , Linkedin , Exchange Commission On , National Institute Of Health , European Union , North America , Middle East , Forward Looking Statement , Private Securities Litigation Reform Act , Apelli Annual Report , Sobi Media , Genetics Home , Accessed November ,